Xylazine Scheduling Didn't Shrink the Tranq Crisis. It Created a Worse One.

Philadelphia’s street dope told the story before the federal government caught up. In May 2024, medetomidine turned up in 29% of the city’s tested dope samples, xylazine in 97%. By March 2026, those numbers had nearly flipped: medetomidine in 90%, xylazine down to 28%. Same family of veterinary sedative. A different, worse drug.

Xylazine’s crackdown didn’t shrink the tranq crisis. It swapped in a drug the health system isn’t ready for.

Medetomidine and xylazine are cousins — both animal tranquilizers made to sedate horses and dogs, neither approved for use in people. Xylazine is the one that causes the flesh wounds that made “tranq” a household word; medetomidine mostly doesn’t. Instead it can drop a person’s heart rate to as low as 32 beats a minute and trigger a withdrawal that starts within hours and can cause heart attacks and a brain-swelling complication called posterior reversible encephalopathy syndrome. Naloxone still reverses the fentanyl almost always mixed in — 98% of positive samples in one CDC sentinel-site study had both — but it does nothing for the sedative itself. People keep breathing. They don’t wake up.

The timing isn’t a coincidence. A new study in the International Journal of Drug Policy compared nine states that made xylazine a controlled substance by name against five that only criminalized it more broadly. Scheduling produced no significant drop in xylazine detections — but it did correlate with roughly 1,536 additional medetomidine detections per 100,000 forensic lab reports. “Our findings provide a cautionary tale against these supply-side drug control policies,” lead author David Zhu told Healio. National lab data backs him up: medetomidine detections went from 247 samples in 2023 to 8,233 in 2025.

The CDC’s April response was itself a departure — the first time the agency has used a Health Alert Network notice for an unregulated street drug rather than a disease outbreak. Filter flagged a framing problem inside it: officials called medetomidine “naloxone-resistant,” when the real issue is that naloxone was never built to touch a non-opioid sedative at all.

The tools that could catch it are getting harder to get. Medetomidine test strips run about $200 for 100, against $35 for fentanyl strips, and federal grant rules now bar SAMHSA money from paying for drug-checking supplies at all. The North Carolina Harm Reduction Coalition says that restriction is landing exactly as the substance it can’t afford to test for spreads up the Atlantic coast. Harm reduction workers already tell people in medetomidine withdrawal to get to an ER — the problem is how many ERs still haven’t been told what they’re looking at.

Every dollar a state spent scheduling xylazine bought a drug the health system understands less, not more. That’s not an argument against ever regulating a dangerous sedative. It’s an argument against mistaking a scheduling bill for a public health response, and against gutting the drug-checking and wound-care infrastructure that’s the only thing keeping pace with whatever replaces xylazine next.